1. Home
  2. TRMK vs VRDN Comparison

TRMK vs VRDN Comparison

Compare TRMK & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trustmark Corporation

TRMK

Trustmark Corporation

HOLD

Current Price

$41.03

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$33.13

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRMK
VRDN
Founded
1889
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.7B
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
TRMK
VRDN
Price
$41.03
$33.13
Analyst Decision
Buy
Strong Buy
Analyst Count
3
13
Target Price
$42.67
$41.17
AVG Volume (30 Days)
265.3K
1.3M
Earning Date
01-27-2026
02-26-2026
Dividend Yield
2.35%
N/A
EPS Growth
10.82
N/A
EPS
3.66
N/A
Revenue
$773,338,000.00
$70,789,000.00
Revenue This Year
$58.33
$26,257.62
Revenue Next Year
$4.57
$4.54
P/E Ratio
$11.15
N/A
Revenue Growth
55.58
23340.07
52 Week Low
$29.77
$9.90
52 Week High
$43.29
$34.29

Technical Indicators

Market Signals
Indicator
TRMK
VRDN
Relative Strength Index (RSI) 53.37 58.30
Support Level $40.15 $31.26
Resistance Level $43.29 $34.29
Average True Range (ATR) 1.01 1.35
MACD 0.08 0.04
Stochastic Oscillator 43.62 76.13

Price Performance

Historical Comparison
TRMK
VRDN

About TRMK Trustmark Corporation

Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Share on Social Networks: